Annual Statements Open main menu

GREEN VISION BIOTECHNOLOGY CORP. - Quarter Report: 2017 April (Form 10-Q)

wordproof.doc

 

U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

Form 10-Q

 

Mark One

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended April 30, 2017

 

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______ to _______

 

Commission File No. No. 000-55210

  

GREEN VISION BIOTECHNOLOGY CORP.

(Exact name of registrant as specified in its charter)

  

Nevada

 

7380

 

98-1060941

(State or Other Jurisdiction

of Incorporation or Organization)

 

(Primary Standard Industrial

Classification Number)

 

(IRS Employer

Identification Number)

 

1255 W. Rio Salado Parkway

Suite 215

Tempe, AZ 85281

(Address and telephone number of principal executive offices)

 

__________________________________________________________

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by checkmark whether the issuer: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

 

Indicate by check mark whether the registrant is a large accelerated filed, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

 

Large accelerated filer

¨

Accelerated filer

¨

Non-accelerated filer

¨

Smaller reporting company

x

 

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes x No o

 

Applicable Only to Issuer Involved in Bankruptcy Proceedings During the Preceding Five Years. N/A

 

Indicate by checkmark whether the issuer has filed all documents and reports required to be filed by Section 12, 13 and 15(d) of the Securities Exchange Act of 1934 after the distribution of securities under a plan confirmed by a court. Yesx No o

 

Applicable Only to Corporate Registrants

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the most practicable date: As of May 11, 2017 there were 60,790,000 shares of Common Stock of the issuer outstanding.

 

 
 
 
 

TABLE OF CONTENTS

 

 

 

 

Page

 

PART I.

FINANCIAL INFORMATION

 

 

 

 

 

 

 

Item 1.

Financial Statements (Unaudited)

 

F-1

 

 

Balance Sheets as of April 30, 2017 and January 31, 2017

 

F-1

 

 

Statements of Operations for the three months ended April 30, 2017 and 2016

 

F-2

 

 

Statements of Cash Flows for the three months ended April 30, 2017 and 2016

 

F-3

 

 

Notes to Financial Statements

 

F 4-5

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

3

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

 

6

 

Item 4.

Controls and Procedures

 

6

 

 

 

 

 

 

PART II.

OTHER INFORMATION

 

 

 

 

 

 

 

 

Item 1.

Legal Proceedings

 

7

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

 

7

 

Item 3.

Defaults Upon Senior Securities

 

7

 

Item 4.

Submission of Matters to a Vote of Security Holders

 

7

 

Item 5.

Other Information

 

7

 

Item 6.

Exhibits

 

7

 

 

Signatures

 

8

 

 

 

2

 
 

  

PART I. FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

 

GREEN VISION BIOTECHNOLOGY CORP.

BALANCE SHEETS

 (UNAUDITED)

 

 

 

April 30,

2017

 

 

January 31,

2017

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

Current Assets

 

 

 

 

 

 

Cash and cash equivalents

 

$ -

 

 

$ -

 

Total current assets

 

 

-

 

 

 

-

 

Total Assets

 

$ -

 

 

$ -

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' DEFICIT

 

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

 

 

Current Liabilities

 

 

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

$ 29,595

 

 

$ 6,944

 

Note payable

 

 

84,704

 

 

 

49,704

 

Advances and loans from related party

 

 

50,000

 

 

 

50,000

 

Total current liabilities

 

 

164,299

 

 

 

106,648

 

Total Liabilities

 

 

164,299

 

 

 

106,648

 

 

 

 

 

 

 

 

 

 

Stockholders' Deficit

 

 

 

 

 

 

 

 

Common stock, par value $0.001; 750,000,000 shares authorized, 60,790,000 shares issued and outstanding

 

 

60,790

 

 

 

60,790

 

Additional paid in capital

 

 

(16,862 )

 

 

(16,862 )

Accumulated deficit

 

 

(208,227 )

 

 

(150,576 )

Total Stockholders' Deficit

 

 

(164,299 )

 

 

(106,648 )

 

 

 

 

 

 

 

 

 

Total Liabilities and Stockholders' Deficit

 

$ -

 

 

$ -

 

 

The accompanying notes are an integral part of these financial statements

 

 
F-1
 
Table of Contents

  

GREEN VISION BIOTECHNOLOGY CORP.

STATEMENTS OF OPERATIONS

 FOR THE THREE MONTH PERIODS ENDED APRIL 30, 2017 AND 2016

 (UNAUDITED)

 

 

 

Three Months Ended

 

 

 

April 30, 2017

 

 

April 30, 2016

 

 

 

 

 

 

 

 

REVENUES

 

$ -

 

 

$ -

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

General and administrative expenses

 

 

57,651

 

 

 

7,695

 

Total Operating Expenses

 

 

57,651

 

 

 

7,695

 

 

 

 

 

 

 

 

 

 

LOSS BEFORE INCOME TAXES

 

 

(57,651 )

 

 

(7,695 )

Income taxes

 

 

-

 

 

 

-

 

NET LOSS

 

$ (57,651 )

 

$ (7,695 )

 

 

 

 

 

 

 

 

 

NET LOSS PER SHARE: BASIC AND DILUTED

 

$ (0.00 )

 

$ (0.00 )

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED

 

 

60,790,000

 

 

 

60,790,000

 

 

The accompanying notes are an integral part of these financial statements

 

 
F-2
 
Table of Contents

  

GREEN VISION BIOTECHNOLOGY CORP.

STATEMENTS OF CASH FLOWS

FOR THE THREE MONTH PERIODS ENDED APRIL 30, 2017 AND 2016

(UNAUDITED)

 

 

 

Three months

ended

April 30,

2017

 

 

Three months

ended

April 30,

2016

 

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

 

 

Net loss

 

$ (57,651 )

 

 

(7,695 )

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Changes in assets and liabilities

 

 

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

 

22,651

 

 

 

4,604

 

CASH FLOW USED IN OPERATING ACTIVITIES

 

 

(35,000 )

 

 

(3,091 )

CASH FLOW FROM FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

Proceeds from note payable

 

 

35,000

 

 

 

-

 

Advances and loans from related party

 

 

-

 

 

 

3,091

 

CASH FLOWS PROVIDED BY FINANCING ACTIVITIES

 

 

35,000

 

 

 

3,091

 

NET CHANGE IN CASH

 

 

-

 

 

 

-

 

Cash, beginning of period

 

 

-

 

 

 

-

 

Cash, end of period

 

$ -

 

 

 

-

 

SUPPLEMENTAL CASH FLOW INFORMATION:

 

 

 

 

 

 

 

 

Interest paid

 

$ -

 

 

 

-

 

Income taxes paid

 

$ -

 

 

 

-

 

 

The accompanying notes are an integral part of these financial statements

 

 
F-3
 
Table of Contents

 

GREEN VISION BIOTECHNOLOGY CORP.

NOTES TO THE FINANCIAL STATEMENTS

APRIL 30, 2017

(Unaudited)

 

NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS

 

Green Vision Biotechnology Corp. (the “Company”), formerly known as Vibe Wireless Corp., formerly known as Any Translation Corp., was incorporated under the laws of the State of Nevada on July 5, 2012. We were founded to be in the business of translation and interpretation. The Company undertook translation and interpretation projects for various fields from business, economics, to science issues. All operating projects were customer tailored with freelancers that operated in their mother-tongue. The Company later adopted a business plan to pursue business opportunities in the global telecommunications industry. We are presently in the process of exploring other business opportunities.

 

On November 12, 2015, we changed our name to Vibe Wireless Corp in connection with merging with our wholly-owned subsidiary. This name change and our ticker symbol change was acknowledged by FINRA and effected in the market on November 23, 2015.

 

On September 30, 2016, the Company filed a Certificate of Amendment with the Nevada Secretary of State (the “Nevada SOS”) whereby it amended its Articles of Incorporation by increasing the Company’s authorized number of shares of common stock from 75 million to 750 million and increasing all of its issued and outstanding shares of common stock at a ratio of ten (10) shares for every one (1) share held. The Company’s Board of Directors approved this amendment on September 30, 2016. This stock split has been retroactively applied.

 

On September 30, 2016, the Company filed Articles of Merger with the Nevada SOS whereby it entered into a statutory merger with its wholly-owned subsidiary, Green Vision Biotechnology Corp. pursuant to Nevada Revised Statutes 92A.200 et. seq. The effect of such merger is that the Company is the sole surviving entity and changed its name to “Green Vision Biotechnology Corp.”

 

On September 30, 2016, the Company filed an Issuer Company-Related Action Notification Form with FINRA requesting that the aforementioned forward split and name change be effected in the market. The Company also requested that its ticker symbol be changed to “GVBT”. Such notification form is being reviewed by FINRA. This name change and our ticker symbol change was acknowledged by FINRA and effected in the market on November 27, 2016.

 

NOTE 2 – BASIS OF PRESENTATION AND GOING CONCERN

 

BASIS OF ACCOUNTING

 

The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the Securities and Exchange Commission (the "SEC") for interim financial reporting. Accordingly, these financial statements do not include all information and footnote disclosures required for an annual set of financial statements prepared under United States generally accepted accounting principles. In the opinion of our management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the financial position, results of operations and cash flows as of April 30, 2017 and for all interim periods presented herein have been reflected in these financial statements and the notes there to. Interim results for the three months ended April 30, 2017 are not necessarily indicative of the results to be expected for the fiscal year as a whole. These financial statements should be read in conjunction with the audited financial statements and accompanying notes as included in the Form 10-K for the year ended January 31, 2017.

 

GOING CONCERN

 

The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses resulting in an accumulated deficit of $208,227 as of April 30, 2017 and further losses are anticipated in the development of its business raising substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and, or, to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and, or, private placement of common stock. These financials do not include any adjustments relating to the recoverability and reclassification of recorded asset amounts, or amounts and classifications of liabilities that might result from this uncertainty.

 

 
F-4
 
Table of Contents

  

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Recent Accounting Pronouncements

 

The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

 

NOTE 3 – RELATED PARTY TRANSACTIONS

 

On August 28, 2015, the Company’s new officer and director entered into an agreement to loan up to $50,000 to the Company, accruing interest at 8%, due on September 1, 2016, and unsecured. The maturity date of the Note has been extended to June 30, 2017.

 

The balance due to advances and loans from related parties was $50,000 as of April 30, 2017 and January 31, 2017 respectively.

 

NOTE 4 – NOTE PAYABLE

 

Beginning in September 2016, Hong Kong Prolific Mineral Resources Limited, a third party, agreed to loan the Company funds on an on-going basis to be used for working capital accruing interest at 8%, due on January 31, 2018. The Company has received $35,000 in loan proceeds during the three months ended April 30, 2017. The note payable balance is $84,704 and $49,704 as of April 30, 2017 and January 31, 2017, respectively.

 

NOTE 5 – SUBSEQUENT EVENT

 

As reported in the Company’s Current Report on Form 8-K filed on May 4, 2017, effective May 3, 2017, the Company accepted the resignation of Edward P. Mooney as the sole officer of the Company and as the sole member of the Company’s board of directors. The resignation of Mr. Mooney was not due to any disagreement with the Company on any matter relating to its operations, policies or practices. Simultaneously, Mr. Ma Wai Kin, was elected as the Company’s President, Secretary, Treasurer and a member of the Board of Directors.

 

Biography

 

Ma Wai Kin

 

Mr. Ma has all-round experiences with Hong Kong and China listed companies including project development, planning design, sales and marketing management, leasing and property management, market research and feasibility studies, CRM and branding. From 1997 to 2004, he worked as a deputy general manager for Agile International Company Limited, a listed company in Hong Kong which specializes in Peoples Republic of China property development. He was primarily responsible for promoting the brand development of the company and coordinating marketing activities, events and projects. From 2005 to 2006, he worked as the Sales and Marketing Manager for Chuang’s Consortium Limited. From 2007 to 2009, he worked as an assistant general manager for Tysan Land (Shanghai) Limited, a member company of a listed company in Hong Kong, responsible for implementing sales and marketing campaigns. Since August 2009, he works as an independent consultant in Hong Kong advising on the marketing aspect of various projects including business development of Sino-Australia kindergartens, planning development of TCM Park in Hengqin, Peoples Republic of China and overseas investment projects in Australia.

 

Mr. Ma received a Bachelor of Arts degree from the University of Toronto in 1985, and a Master of Science (Marketing) degree from the Chinese University of Hong Kong in 2005.

 

 
F-5
 
Table of Contents

  

FORWARD LOOKING STATEMENTS

 

Statements made in this Form 10-Q that are not historical or current facts are "forward-looking statements". These statements often can be identified by the use of terms such as "may," "will," "expect," "believe," "anticipate," "estimate," "approximate" or "continue," or the negative thereof. We intend that such forward-looking statements be subject to the safe harbors for such statements. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Any forward-looking statements represent management's best judgment as to what may occur in the future. However, forward-looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statement or to reflect the occurrence of anticipated or unanticipated events.

 

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

 

GENERAL

 

As disclosed in our Current Report on Form 8-K dated May 3, 2017 there has been a change in our management.

 

Results of Operations

 

Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation.

 

We expect we will require additional capital to meet our long term operating requirements. We expect to raise additional capital through, among other things, the sale of equity or debt securities.

 

 
3
 
Table of Contents

 

Three Month Period Ended April 30, 2017 Compared to Three Month Period Ended April 30, 2016.

 

During the three month period ended April 30, 2017 we incurred general and administrative expenses of $57,651 compared to $7,695 for the three month period ended April 30, 2016. General and administrative fee expenses incurred during the three month periods ended April 30, 2017 and April 30, 2016 were generally related to corporate overhead, financial and administrative contracted services, and interest expense.

 

Our net loss for the three month period ended April 30, 2017 was $57,651 compared to a net loss of $7,695 for the three month period ended April 30, 2016. During the three month periods ended April 30, 2017 and April 30, 2016 we have not generated any revenue.

 

Liquidity and Capital Resources

 

Three Month Period Ended April 30, 2017

 

As of April 30, 2017 our total assets were $0 compared to $0 at April 30, 2016. As of April 30, 2017 our current liabilities were $164,299. Stockholders’ deficit was $164,299 as of April 30, 2017 compared to stockholders' deficit of $106,648 as of January 31, 2017. As of April 30, 2017, we had negative working capital of $164,299.

 

 
4
 
Table of Contents

 

Cash Flows from Operating Activities

 

We have not generated positive cash flows from operating activities. For the three month period ended April 30, 2017, net cash flows used in operating activities was $35,000. Net cash flows used in operating activities was $3,091 for the three month period ended April 30, 2016.

 

Cash Flows from Investing Activities

 

For the three month period ended April 30, 2017 and 2016, the Company has not generated any cash flows from investing activities.

 

Cash Flows from Financing Activities

 

Since inception we have financed our operations primarily from advances and loans from shareholders, the issuance of equity, or loans from third parties. For the three month period ended April 30, 2017 net cash provided by financing activities consisted of $35,000 loaned from a Third Party, compared to $3,091 in net cash provided during the same period from the previous year which consisted of loans from a Related Party.

 

Plan of Operation and Funding

 

We expect that working capital requirements will continue to be funded through a combination of our existing funds, loans from Third Parties, other debt facilities, or further issuances of securities. Our working capital requirements are expected to increase in line with the growth of our business.

 

Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund our operations over the next three months. We have no lines of credit or other bank financing arrangements. Generally, we have financed operations to date through the proceeds of the private placement of equity and debt instruments. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) acquisition of operating equipment; (ii) developmental expenses associated with a start-up business; and (iii) marketing expenses. We intend to finance these expenses with further issuances of securities, and debt issuances. Thereafter, we expect we will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders. Further, such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations. We will have to raise additional funds in the next twelve months in order to sustain and expand our operations. We currently do not have a specific plan of how we will obtain such funding; however, we anticipate that additional funding will be in the form of equity financing from the sale of our common stock. We have and will continue to seek to obtain short-term loans from our directors, although no future arrangement for additional loans has been made. We do not have any agreements with our directors concerning these loans. We do not have any arrangements in place for any future equity financing.

 

Off-Balance Sheet Arrangements

 

As of the date of this Quarterly Report, we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

 

 
5
 
Table of Contents

 

Going Concern

 

The independent auditors' report accompanying our January 31, 2017 audited financial statements contained an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern. The financial statements have been prepared "assuming that we will continue as a going concern," which contemplates that we will realize our assets and satisfy our liabilities and commitments in the ordinary course of business.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

No report required.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of April 30, 2017. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Such officer also confirmed that there was no change in our internal control over financial reporting during the three month period ended April 30, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 
6
 
Table of Contents

 

PART II. OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

Management is not aware of any legal proceedings contemplated by any governmental authority or any other party involving us or our properties. As of the date of this Quarterly Report, no director, officer or affiliate is (i) a party adverse to us in any legal proceeding, or (ii) has an adverse interest to us in any legal proceedings. Management is not aware of any other legal proceedings pending or that have been threatened against us or our properties.

  

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

No report required.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

No report required.

 

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

 

No report required.

 

ITEM 5. OTHER INFORMATION

 

No report required.

 

ITEM 6. EXHIBITS

 

Exhibits:

  

31.1

 

Certification of Chief Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).

 

 

 

32.1

 

Certifications pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 
7
 
Table of Contents

  

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

GREEN VISION BIOTECHNOLOGY CORP. 

 

 

 

 

Dated: May 12, 2017

By:

/s/ MA WAI KIN

 

 

Name:

MA WAI KIN

 

 

Title:

President

 

 

 

8